UK company developing complex botanical pharmaceuticals from extracts of Cannabis Sativa
As former members of the GW Pharmaceuticals executive team, where we learned to develop FDA approved medicines from the cannabis plant, we have established Neurone to enable us to pursue the development and approval of the next generation of cannabis based pharmaceuticals.
We use complex botanical extracts, obtained from botanical raw material grown in our licensed growing facility, to create novel extract based pharmaceutical products.
We will develop IP protected, complex botanical medicines, executing the clinical trials required to secure FDA and other international regulatory approvals in order to enable prescribing and reimbursement needed to achieve broad patient access.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Chilvester Hill, Chilvester Lodge,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- cannabis, botanical medicines, controlled drugs, FDA, clinical trials, cannabinoid science, CBD, THC, Good Manufacturing Practice, Botanical extracts, Analytical Chemistry.
- HQ
- Calne, England
Neurone Ltd Questions
Neurone Ltd's LinkedIn profile is https://uk.linkedin.com/company/neurone-limited
Neurone Ltd has
4 employees.
View email and phone details for 4
employees at Neurone Ltd.
Neurone Ltd's industry is
Biotechnology Research
Neurone Ltd's top competitors are
Global Impact Ventures,
Phytome Life Sciences,
Kadmos Capital Ltd,
Ninety3 Biotech,
Psiclone Ltd,
Biomavericks,
Phaim Pharma Ltd,
Rs&rs Scientific,
Gutsee Health,
Sevenless Therapeutics.
Neurone Ltd's categories are Biotechnology Research
Neurone Ltd's founding year is 2021
